Arcellx
ACLX
Performance
About Arcellx
Arcellx is a biotechnology company focused on developing innovative cell therapies for cancer and autoimmune diseases. The company emphasizes reimagining cell therapy and advancing how cancer is treated through engineered cellular approaches. Headquartered with operations described globally, Arcellx positions itself in oncology and immunology with a pipeline aimed at translating scientific breakthroughs into new treatments. The site highlights a mission to pursue a cure for cancer and to push the boundaries of cellular medicine.
Recent News
#58798
Top Biotech Deals in March 2026
Gilead Shows Belief in Its Partner’s Cancer Treatment with $7.8 Billion Buyout
STAT+: Gilead to Buy Cancer Biotech Tubulis for More than $3 Billion
Stock Movers: Gilead Sciences, Merck, Domino's (Podcast)
Gilead to Buy US Biotech Arcellx for up to US$7.8 Billion
Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks
#58853
CellCentric Secures $220M in Europe’s Biggest Private Biotech Fundraise of 2026
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
Gilead Wipes Out Most of Arcellx Workforce
Approaches to Reducing Toxicity and Side Effects in Cell and Gene Therapy